The global smart insulin pens market attained a value of USD 74.7 million in 2022, driven by increasing prevalence of diabetes worldwide. The market is expected to grow at a CAGR of 12.26% during the forecast period of 2023-2031 to attain a value of USD 211.2 million by 2031.
Moreover, advancements in technology and the development of smart insulin pens with enhanced capabilities have fuelled market expansion. These pens are equipped with electronic components, connectivity features, dose calculators, data logging, and reminders, providing individuals with diabetes convenient and user-friendly tools for insulin dosing and management. The integration of mobile apps and cloud-based platforms further enhances the functionality and accessibility of smart insulin pens.
Furthermore, the shift towards personalized and connected healthcare has played a crucial role in market demand for smart insulin pens. These devices align with the growing trend of patient-centred care and self-management in diabetes management. Smart insulin pens empower individuals with diabetes to actively monitor and track their insulin doses, facilitating better treatment adherence, personalized dose adjustments, and improved glycaemic control.
Smart Insulin Pens: Introduction
Smart insulin pens are technologically advanced devices used by individuals with diabetes to administer insulin. These pens are equipped with electronic components and connectivity features that allow for enhanced tracking, monitoring, and management of insulin administration. Smart insulin pens offer several uses and benefits in diabetes management.The benefits of smart insulin pens include:
- Accurate Insulin Dosing: Smart insulin pens offer precise insulin dosing capabilities, reducing the risk of dosing errors and ensuring individuals receive the correct amount of insulin. This enhances insulin therapy efficacy and improves overall glycaemic control
- Simplified Insulin Management: Smart insulin pens streamline insulin management by automating data tracking and logging. Individuals no longer need to manually record their insulin doses, as the pens automatically capture and store the information. This simplifies diabetes self-care and provides a comprehensive record of insulin administration
- Enhanced Treatment Monitoring: The connectivity features of smart insulin pens facilitate improved treatment monitoring. The recorded insulin data can be analysed over time, allowing individuals and healthcare providers to identify patterns, make adjustments to insulin dosing, and optimize diabetes management
- Adherence Support: Smart insulin pens can help individuals adhere to their insulin regimen by providing reminders for insulin injections and tracking missed doses. These features promote medication adherence and help individuals stay on track with their treatment plan
- Patient Empowerment and Engagement: Smart insulin pens empower individuals to take an active role in their diabetes management. The availability of real-time insulin data, personalized dose recommendations, and tracking capabilities fosters self-monitoring, engagement, and better understanding of insulin therapy
Smart Insulin Pens Market Segmentations
The market can be categorised into products, type, connectivity type, application, and region.Market Breakup by Products
- Smart Insulin Pens
- Adaptors for Conventional Pens
- Disposable
- Reusable
Market Breakup by Type
- First Generation Pens
- Second Generation Pens
Market Breakup by Connectivity Type
- Bluetooth
- USB
Market Breakup by Application
- Type 1 Diabetes
- Type 2 Diabetes
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Smart Insulin Pens Market Overview
The market has experienced significant growth and is expected to continue expanding in the coming years. One of the primary drivers of market growth is the increasing prevalence of diabetes worldwide. The rising global incidence of diabetes, particularly type 1 and type 2 diabetes, has created a growing population of individuals who require insulin therapy for managing their condition. Smart insulin pens offer advanced features and benefits over traditional insulin pens, making them an attractive option for diabetes management.Moreover, advancements in technology and the development of smart insulin pens with enhanced capabilities have fuelled market expansion. These pens are equipped with electronic components, connectivity features, dose calculators, data logging, and reminders, providing individuals with diabetes convenient and user-friendly tools for insulin dosing and management. The integration of mobile apps and cloud-based platforms further enhances the functionality and accessibility of smart insulin pens.
Furthermore, the shift towards personalized and connected healthcare has played a crucial role in market demand for smart insulin pens. These devices align with the growing trend of patient-centred care and self-management in diabetes management. Smart insulin pens empower individuals with diabetes to actively monitor and track their insulin doses, facilitating better treatment adherence, personalized dose adjustments, and improved glycaemic control.
Key Players in the Global Smart Insulin Pens Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the smart insulin pens market are as follows:- Emperra GmbH
- Medtronic Plc
- Novo Nordisk
- Pendiq
- Sanofi FA
- Berlin-Chemie AG
- Bigfoot Biomedical
- Digital Medics Pty Ltd
- Eli Lilly and Company
- Jiangsu Deflu Medical Device Co. Ltd
Table of Contents
1 Preface
3 Global Smart Insulin Pens Market Overview
4 Global Smart Insulin Pens Market Dynamics
5 Global Smart Insulin Pens Market Segmentation
6 North America Smart Insulin Pens Market
7 Europe Smart Insulin Pens Market
8 Asia Pacific Smart Insulin Pens Market
9 Latin America Smart Insulin Pens Market
10 Middle East and Africa Smart Insulin Pens Market
11 Regulatory Framework
12 Patent Analysis
13 Grants Analysis
14 Clinical Trials Analysis
15 Funding and Investment Analysis
16 Partnership and Collaborations Analysis
17 Supplier Landscape
19 Company Competitiveness Analysis (Additional Insight)
20 Payment Methods (Additional Insight)
Companies Mentioned
- Emperra GmbH
- Medtronic Plc
- Novo Nordisk
- Pendiq
- Sanofi FA
- Berlin-Chemie AG
- Bigfoot Biomedical
- Digital Medics Pty Ltd.
- Eli Lilly and Company
- Jiangsu Deflu Medical Device Co. Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 160 |
Published | July 2023 |
Forecast Period | 2023 - 2031 |
Estimated Market Value ( USD | $ 83.8 Million |
Forecasted Market Value ( USD | $ 211.2 Million |
Compound Annual Growth Rate | 12.2% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |